Prothena
$9.72
55
+$0.47+5.08% Tuesday 20:00
Statistics
Day High
9.85
Day Low
9.33
52W High
12.45
52W Low
4.32
Volume
651,764
Avg. Volume
513,008
Mkt Cap
523.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.348333
Actual EPS
N/A
Financials
-2,520.57%Profit Margin
Unprofitable19.37MRevenue
-488.18MNet Income
Analyst Ratings
$24.25Average Price Target
The highest estimate is 36.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 50%
Hold 50%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PRTA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Roche
RHHBY
Mkt Cap258.9B
Abbvie
ABBV
Mkt Cap385.18B
AMGEN
AMGN
Mkt Cap160.66B
Pfizer
PFE
Mkt Cap140.15B
Novartis
NVS
Mkt Cap237.61B
Merck
MRK
Mkt Cap214.76B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
About
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Show more...
CEO
Dr. Gene G. Kinney Ph.D.
Employees
163
Country
IE
ISIN
IE00B91XRN20
Listings
0 Comments
Share your thoughts
FAQ
What is Prothena stock price today?▼
The current price of PRTA is $9.72 USD — it has increased by +5.08% in the past 24 hours. Watch Prothena stock price performance more closely on the chart.
What is Prothena stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Prothena stocks are traded under the ticker PRTA.
Is Prothena stock price growing?▼
PRTA stock has risen by +4.4% compared to the previous week, the month change is a +12.11% rise, over the last year Prothena has showed a -17.21% decrease.
What is Prothena market cap?▼
Today Prothena has the market capitalization of 523.26M
When is the next Prothena earnings date?▼
Prothena is going to release the next earnings report on May 13, 2026.
What were Prothena earnings last quarter?▼
PRTA earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.56 USD resulting in a +28.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prothena revenue for the last year?▼
Prothena revenue for the last year amounts to 19.37M USD.
What is Prothena net income for the last year?▼
PRTA net income for the last year is -488.18M USD.
How many employees does Prothena have?▼
As of April 01, 2026, the company has 163 employees.
In which sector is Prothena located?▼
Prothena operates in the Health Care sector.
When did Prothena complete a stock split?▼
Prothena has not had any recent stock splits.
Where is Prothena headquartered?▼
Prothena is headquartered in Dublin, IE.